Journal Club - Low dose atropine has been found to be effective in treating myopia - Video

Published On 2022-05-09T09:45:23+05:30 | Updated On 9 May 2022 9:45 AM IST

Overview

Previous reviews and meta-analyses reported that among various treatment options available, topical atropine shows a maximum reduction in myopia progression. A recent Study in Scientific Reports has evaluated the efficacy and safety of low-dose atropine compared to placebo in the Indian population and also to study the impact of various modifiable and non-modifiable factors on myopia progression (MP) and drug efficacy (DE).

The Study was a single-centred prospective placebo-controlled interventional study, which included a total of 43 participants aged 6–16 years with progressive myopia. All the participants received 0.01% atropine in the right eyes (treatment) and placebo in the left eyes (control) for 1-year. The main outcome measures were annual myopia progression and axial length elongation (ALE) in treatment and control eyes and their drug efficacy.

It was then found that, myopia progression showed 63.89% reduction with respective axial length elongation at 44.44% reduction. Reduction in both the parameters was statistically significant in all children irrespective of age-group, baseline MP, family history, screen- time, near and outdoor-time. The researchers concluded that 0.01% atropine was effective and safe in retarding myopia progression and axial length elongation in Indian eyes, lifestyle and habits might also have a crucial role to play in it.

We now have with us, the lead author of this study, Dr. Shweta Chaurasia, Assistant Professor at the Advanced Eye Centre, PGIMER Chandigarh.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751